What does a positive fibrin test in peritoneal dialysis effluent indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Positive Fibrin Test in Peritoneal Dialysis Effluent

A positive fibrin test in peritoneal dialysis effluent indicates active intraperitoneal coagulation and fibrin formation, which occurs both during normal PD therapy and is markedly elevated during peritonitis, serving as a marker of peritoneal inflammation and potential membrane dysfunction.

Clinical Significance

Normal PD State (Without Peritonitis)

  • Baseline fibrin formation occurs continuously in all PD patients, even when clinically stable, reflecting ongoing thrombin-induced intraperitoneal fibrin generation during regular dialysis exchanges 1
  • Fibrin monomer levels reach approximately 24.5 ± 7.1 micrograms/mL after a 4-hour dwell in stable patients, with concentrations increasing progressively throughout the dwell time 1
  • The dialysate-to-plasma ratios of fibrin-related antigens are significantly higher than expected from simple plasma diffusion, confirming local intraperitoneal production rather than systemic origin 1
  • This represents a high rate of intraperitoneal fibrin turnover that is balanced by concurrent fibrinolysis under normal conditions 1, 2

During Peritonitis

  • Fibrin levels increase dramatically during bacterial peritonitis, with fibrin monomer concentrations reaching 972 ± 3.2 micrograms/mL (approximately 40-fold higher than baseline) 1
  • The ratio between fibrin monomer and fibrin degradation products increases 2.4-times during peritonitis, indicating an imbalance where coagulation exceeds fibrinolysis 1
  • This imbalance reflects disturbed peritoneal hemostasis with excessive fibrin deposition that may contribute to peritoneal membrane damage 2
  • Fibrin degradation products (FDPs) also increase significantly during peritonitis (16.4 ± 2.9 micrograms/L versus 1.0 ± 0.3 micrograms/L in stable patients) 1

Diagnostic Interpretation Algorithm

Step 1: Assess Clinical Context

  • If patient has cloudy effluent, abdominal pain, or fever: Positive fibrin test supports peritonitis diagnosis but must be confirmed with white cell count >100 cells/μL and culture 3
  • If patient is clinically stable: Positive fibrin test represents normal baseline fibrin turnover and does not indicate pathology 1

Step 2: Timing Considerations

  • Never interpret fibrin tests during or within 1 month after peritonitis resolution, as peritonitis transiently alters all peritoneal transport characteristics and produces falsely abnormal findings 4, 5
  • Wait at least 4 weeks after peritonitis resolution before obtaining any peritoneal membrane function tests 4

Step 3: Correlation with Other Markers

  • Elevated fibrin should be interpreted alongside IL-6 and FDP levels, which correlate positively with each other and reflect chronic peritoneal inflammation 6
  • The combination of elevated IL-6 and FDPs correlates with increased permeability to large molecules (albumin, α2-macroglobulin), indicating progressive peritoneal membrane deterioration 6
  • Serial measurements showing increasing fibrin/FDP levels over time predict peritoneal deterioration and potential development of encapsulating peritoneal sclerosis 6

Clinical Implications

For Acute Management

  • Positive fibrin test with clinical peritonitis symptoms warrants immediate antibiotic therapy plus intraperitoneal heparin administration 2
  • Heparin treatment significantly reduces fibrin monomer, TAT, and F1+2 levels within 7 days of peritonitis treatment 2

For Long-Term Monitoring

  • Longitudinal tracking of fibrin-related markers helps predict peritoneal membrane failure, particularly when combined with IL-6 and FDP measurements 6
  • Progressive increases in fibrin markers correlate with increased D/P ratios for large molecules (albumin, α2-macroglobulin) but not necessarily with D/P creatinine from standard PET testing 6
  • This dissociation means standard peritoneal equilibration tests may miss early peritoneal deterioration that fibrin markers can detect 6

Critical Pitfalls to Avoid

  • Do not confuse fibrin in effluent with simple cloudy dialysate: Cloudy effluent has multiple causes including leukocytes, eosinophils, red blood cells, chyle, or even malignant cells 7
  • Do not obtain fibrin measurements during acute illness or recent peritonitis: Results will be transiently elevated and non-interpretable for baseline membrane function 4
  • Do not rely solely on D/P creatinine to assess peritoneal membrane health: Fibrin-related markers and large molecule permeability provide complementary information about membrane deterioration not captured by standard PET 6
  • Do not ignore progressively rising fibrin markers in stable patients: This may indicate subclinical chronic inflammation leading to ultrafiltration failure and eventual technique failure 6

References

Research

Coagulation- and fibrinolysis-related antigens in plasma and dialysate of CAPD patients.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 1997

Research

Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1995

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Criteria for PD-Associated Peritonitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 2005

Research

Lymphoma-mimicking peritonitis in a patient on continuous ambulatory peritoneal dialysis (CAPD).

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.